Sun Pharma Advanced (SPARC) | Stock Overview & Key Data
Sun Pharma Advanced Performance Comparison
Stock Range
Today's Range
Low: ₹130.40
High: ₹133.29
on October 6, 2025
52 Week Range
Low: ₹109.30
High: ₹241.00
on March 3, 2025
on December 16, 2024
All-Time High: ₹875.00 on April 24, 2006
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR42.8B
EPS
-9.19
P/E Ratio (TTM)
-12.50
Forward P/E
2.38
P/B Ratio
-19.71
PEG Ratio
0.27
Div. Yield
N/A
ROE
157.88%
Beta
0.240
Debt to Equity
-1.24
Financial Highlights
Profitability
Gross Margin
-10.68%
Operating Margin
-568.05%
Profit Margin
-53.22%
Returns and Earnings
Return on Assets (TTM)
-102.08%
Return on Equity (TTM)
157.88%
EBITDA
INR-2.8B
Net Income (TTM)
INR-3.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR1.99
Quarterly Revenue Growth (YoY)
-42.70%
Quarterly Earnings Growth (YoY)
-42.65%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma Advanced SPARC | 42.84B Small-cap | 0.27% | -10.02% | -17.07% | -11.93% | -34.17% | -37.21% | -39.59% | -23.57% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 2.26% | -3.33% | -15.42% | 10.79% | -4.06% | -5.14% | 63.08% | 80.80% |
| Innova Captab INNOVACAP | 48.64B Small-cap | 0.59% | -7.07% | -0.71% | -5.56% | -23.39% | 15.25% | 57.00% | 57.00% |
| Suven Life Sciences SUVEN | 47.99B Small-cap | -0.20% | -3.13% | -15.86% | 58.76% | 63.09% | 46.77% | 186.97% | 307.88% |
| Gujarat Themis GUJTHEM | 46.19B Small-cap | 5.81% | 11.73% | 24.24% | 72.58% | 76.09% | 95.83% | 95.83% | 95.83% |
Ownership & Short Interest
Insider Ownership
72.96%
Institutional Ownership
2.19%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
279K
Average 90-Day Volume
219K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SPARC's 52-week high and low?
- In the last 52 weeks, Sun Pharma Advanced reached a high of ₹241.00 (on December 16, 2024) and a low of ₹109.30 (on March 3, 2025).
- What is the market cap and P/E ratio for SPARC?
- Curious about Sun Pharma Advanced's size and valuation? Its market capitalization stands at 42.84B. When it comes to valuation, the P/E ratio (trailing twelve months) is -12.50, and the forward P/E (looking ahead) is 2.38.
- Does SPARC pay dividends? If so, what's the yield?
- As for dividends, Sun Pharma Advanced isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sun Pharma Advanced's main competitors or similar companies to consider before investing?
When looking at Sun Pharma Advanced, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic -5.14% 63.08% Innova Captab
INNOVACAP48.64B Healthcare Drug Manufacturers - Specialty & Generic 15.25% 57.00% Suven Life Sciences
SUVEN47.99B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Gujarat Themis
GUJTHEM46.19B Healthcare Drug Manufacturers - Specialty & Generic 95.83% 95.83% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sun Pharma Advanced Research Company Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sun Pharma Advanced's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 157.88%, the Debt to Equity ratio from the most recent quarter is -1.24, and its Gross Profit Margin stands at -10.68%.
- What is the recent revenue and earnings growth for SPARC?
- Looking at Sun Pharma Advanced's growth, its revenue over the trailing twelve months (TTM) was INR646M. Compared to the same quarter last year (YoY), quarterly revenue grew by -42.70%, and quarterly earnings saw a YoY growth of -42.65%.
- How much of SPARC stock is held by insiders and institutions?
- Wondering who owns Sun Pharma Advanced stock? Company insiders (like executives and directors) hold about 72.96% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.19%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.